Case-Based Roundtable Meetings Spotlight May 2021: Solid Tumors

Roundtable Discussion: Dorff and Participants Compare PSA Doubling Times and Treatment Decisions in nmCRPC

October 02, 2021

Clinical Articles

One year following treatment with androgen deprivation therapy, a 57-year-old patients with nonmetastatic castration-resistant prostate cancer presented again with a PSA doubling time of 8.6 months and was still nonmetastatic.

Lenvatinib/Everolimus Shows Potential as Second-Line Therapy After CheckMate 9ER Regimen in RCC

May 29, 2021

Clinical Articles

The CheckMate 9ER study compared nivolumab plus cabozantinib with sunitinib and found that as disease becomes less favorable by prognostic risk. Promise has now been shown for this population with the combination of lenvatinib and everolimus.

Roundtable Discussion: Landau Leads Debate on Treatment Decisions for Patients With Metastatic CRPC

May 26, 2021

Clinical Articles

The case of a 75-year-old man with stage T2N0M0 prostate cancer was the topic of discussion between 8 oncologists, a physicians assistant, and a nurse practitioner during a recent Targeted Oncology Case-Based Roundtable event moderated by Daniel Landau, MD.

Cabazitaxel Advances Later-Line Treatment in Metastatic CRPC Setting

May 23, 2021

Clinical Articles

During a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, discussed the results of cabazitaxel as a later-line treatment for patients with metastatic castration-resistant prostate cancer.

Roundtable Discussion: Exploring Factors of a Patient With RR-DTC to Decide Appropriate Treatment

May 23, 2021

Clinical Articles

Steven I. Sherman, MD, FACE, moderated a Targeted Oncology Case-Based Roundtable event during which experts discussed the characteristics of patients with radioiodine-refractory differentiated thyroid cancer and how to consider them when selecting treatment.

Durvalumab After Chemotherapy Helps Manage Toxicities in NSCLC Treatment

May 18, 2021

Clinical Articles

Chemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.